Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. Slamon DJ, et al. Among authors: jerusalem g. J Clin Oncol. 2018 Aug 20;36(24):2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3. J Clin Oncol. 2018. PMID: 29860922 Clinical Trial.
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schütte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S. Capri G, et al. Among authors: jerusalem g. Ann Oncol. 2010 Mar;21(3):474-480. doi: 10.1093/annonc/mdp373. Epub 2009 Oct 8. Ann Oncol. 2010. PMID: 19815649 Free article. Clinical Trial.
["Triple negative" breast cancer].
Freres P, Collignon J, Gennigens C, Scagnol I, Rorive A, Barbeaux A, Coucke PA, Jérusalem G. Freres P, et al. Among authors: jerusalem g. Rev Med Liege. 2010 Mar;65(3):120-6. Rev Med Liege. 2010. PMID: 20411815 Free article. French.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. Among authors: jerusalem g. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.
[Breast cancer and brain metastases].
Rorive A, Collignon J, Martin M, André C, Jerusalem G, Coucke P. Rorive A, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):299-305. Rev Med Liege. 2011. PMID: 21826966 Free article. French.
[Hormone therapy for breast cancer].
Lifrange E, Andre C, Bleret V, Collignon J, Coucke P, Cusumano P, Desreux J, Herman P, Jerusalem G, Kridelka F, Martin M, Rorive A, Van Cauwenberge JR, Colin C. Lifrange E, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):367-71. Rev Med Liege. 2011. PMID: 21826978 Free article. French.
[Systemic chemotherapy and breast cancer].
Collignon J, Rorive A, Martin M, Andre C, Maweja S, Lifrange E, Coucke P, Jerusalem G. Collignon J, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):372-8. Rev Med Liege. 2011. PMID: 21826979 Free article. French.
[Targeted therapies in breast cancer].
Jerusalem G, Collignon J, Rorive A, Lifrange E, André C, Martin M, Maweja S, Coucke P. Jerusalem G, et al. Rev Med Liege. 2011 May-Jun;66(5-6):379-84. Rev Med Liege. 2011. PMID: 21826980 Free article. French.
[Breast cancer in the elderly patient].
Martin M, Collignon J, Rorive A, André C, Bourhaba M, Allepaerts S, Coucke P, Lifrange E, Jerusalem G. Martin M, et al. Among authors: jerusalem g. Rev Med Liege. 2011 May-Jun;66(5-6):400-8. Rev Med Liege. 2011. PMID: 21826984 Free article. French.
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P. Llombart A, et al. Among authors: jerusalem g. Clin Breast Cancer. 2012 Feb;12(1):40-8. doi: 10.1016/j.clbc.2011.08.002. Epub 2011 Oct 19. Clin Breast Cancer. 2012. PMID: 22014381 Clinical Trial.
278 results